Kennett Square, PA, United States of America

Argyrios Georgios Arvanitis


Average Co-Inventor Count = 4.6

ph-index = 10

Forward Citations = 423(Granted Patents)


Company Filing History:


Years Active: 2000-2010

Loading Chart...
13 patents (USPTO):Explore Patents

Title: Argyrios Georgios Arvanitis: Innovator in Pharmaceutical Research

Introduction

Argyrios Georgios Arvanitis is a notable inventor based in Kennett Square, PA (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 13 patents. His work primarily focuses on developing innovative treatments for various psychiatric and neurological disorders.

Latest Patents

Among his latest patents are the Azolo triazines and pyrimidines, which are identified as Corticotropin releasing factor (CRF) antagonists of formula I or II. These compounds are designed for use in treating anxiety, depression, and other psychiatric and neurological disorders. Additionally, they have applications in the treatment of immunological, cardiovascular, or heart-related diseases, as well as colonic hypersensitivity associated with psychopathological disturbances and stress.

Career Highlights

Argyrios has worked with prominent companies in the pharmaceutical industry, including DuPont Pharmaceuticals Company and Bristol-Myers Squibb Pharma Company. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field.

Collaborations

Throughout his career, Argyrios has collaborated with esteemed colleagues such as Robert J. Chorvat and Paul Joseph Gilligan. These partnerships have further enhanced his research capabilities and innovation potential.

Conclusion

Argyrios Georgios Arvanitis stands out as a significant figure in pharmaceutical innovation, with a focus on developing treatments for complex health issues. His contributions continue to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…